JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Search

Certara Inc

Închisă

SectorSănătate

7.17 -0.69

Rezumat

Modificarea prețului

24h

Curent

Minim

6.97

Maxim

7.25

Indicatori cheie

By Trading Economics

Venit

3.5M

1.5M

Vânzări

46K

105M

P/E

Medie Sector

118.571

84.243

Marjă de profit

1.458

Angajați

1,487

EBITDA

-6.5M

23M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+60.03% upside

Dividende

By Dow Jones

Următoarele câștiguri

26 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-557M

1.3B

Deschiderea anterioară

7.86

Închiderea anterioară

7.17

Sentimentul știrilor

By Acuity

50%

50%

144 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Certara Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 feb. 2026, 17:25 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9 feb. 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9 feb. 2026, 23:43 UTC

Market Talk

Gold Falls on Possible Technical Correction -- Market Talk

9 feb. 2026, 23:14 UTC

Market Talk

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9 feb. 2026, 22:29 UTC

Market Talk

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9 feb. 2026, 22:19 UTC

Market Talk

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9 feb. 2026, 22:08 UTC

Market Talk

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9 feb. 2026, 22:01 UTC

Câștiguri

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9 feb. 2026, 21:59 UTC

Câștiguri

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9 feb. 2026, 21:59 UTC

Câștiguri

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9 feb. 2026, 21:58 UTC

Câștiguri

Friedman Industries 3Q Sales $168M >FRD

9 feb. 2026, 21:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

9 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 feb. 2026, 21:48 UTC

Câștiguri

Friedman Industries 3Q EPS 43c >FRD

9 feb. 2026, 21:17 UTC

Câștiguri

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9 feb. 2026, 21:13 UTC

Market Talk

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9 feb. 2026, 21:04 UTC

Câștiguri

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9 feb. 2026, 20:30 UTC

Market Talk

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9 feb. 2026, 20:02 UTC

Market Talk

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9 feb. 2026, 19:42 UTC

Market Talk

Japan's Yield Curve Expected to Flatten -- Market Talk

9 feb. 2026, 19:31 UTC

Market Talk

Nike Seen Regaining Relevance With Consumers -- Market Talk

9 feb. 2026, 19:27 UTC

Market Talk

Gold Climbs Back Over $5,000/oz -- Market Talk

9 feb. 2026, 19:05 UTC

Market Talk

Nike Returns to List of Hottest Brands -- Market Talk

9 feb. 2026, 18:19 UTC

Market Talk

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9 feb. 2026, 17:41 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9 feb. 2026, 17:31 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9 feb. 2026, 17:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

9 feb. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 feb. 2026, 17:17 UTC

Market Talk

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9 feb. 2026, 17:16 UTC

Câștiguri

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Comparație

Modificare preț

Certara Inc Așteptări

Obiectiv de preț

By TipRanks

60.03% sus

Prognoză pe 12 luni

Medie 11.57 USD  60.03%

Maxim 13 USD

Minim 9 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCertara Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

9 ratings

6

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

11.27 / 12.79Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

144 / 352 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat